Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails

Journal of Urology

Volumn 169, Issue 5, 2003, Pages 1742-1744

  Kassouf, Wassim ^a   Tanguay, Simon ^a   Aprikian, Armen G ^a  

^a MONTREAL GENERAL HOSPITAL   (Canada)

Author keywords

Antineoplastic agents, hormonal; Prostatic neoplasms; Treatment failure

Indexed keywords

ANDROGEN; ANTIANDROGEN; BICALUTAMIDE; FLUTAMIDE; NILUTAMIDE; PROSTATE SPECIFIC ANTIGEN;

ADVANCED CANCER; AGED; ANDROGEN BLOOD LEVEL; ARTICLE; CANCER HORMONE THERAPY; CASTRATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG INDICATION; FOLLOW UP; HEADACHE; HUMAN; INTERSTITIAL PNEUMONIA; LIGHT DARK CYCLE; MALE; NAUSEA; PRIORITY JOURNAL; PROSTATE CARCINOMA; TREATMENT FAILURE; TREATMENT OUTCOME; VERTIGO;

EID: 0037404165     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000057795.97626.66     Document Type: Article

References (16)

1. Kelly, Wm. K. and Scher, H. I.: Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. J Urol, 149: 607, 1993
2. Small, E. J. and Srinivas, S.: The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer. Cancer, 76: 1428, 1995
3. Dawson, N. A. and McLeod, D. G.: Dramatic prostate specific antigen decrease in response to discontinuation of megestrol acetate in advanced prostate cancer: expansion of the antiandrogen withdrawal syndrome. J Urol, 153: 1946, 1995
4. Gelmann, E. P.: Molecular biology of the androgen receptor. J Clin Oncol, 20: 3001, 2002
5. Olea, N., Sakabe, K., Soto, A. M. and Sonnenschein, C.: The proliferative effects of "anti-androgens" on the androgen-sensitive human prostate tumor cell line LNCaP. Endocrinology, 126: 1457, 1990
6. Figg, W. D., McCall, N. A. and Sartor, O.: The in vitro response to four antisteroid receptor agents on the hormone-responsive prostate cancer cell line LNCaP. Oncol Rep, 2: 295, 1995
7. Scher, H. I., Liebertz, C., Kelly, W. K., Mazumdar, M., Brett, C., Schwartz, L. et al: Bicalutamide for advanced prostate cancer: the natural versus treated history of disease. J Clin Oncol, 15: 2928, 1997
8. Osborn, J. L., Smith, D. C. and Trump, D. L.: Megestrol acetate in the treatment of hormone refractory prostate cancer. Am J Clin Oncol, 20: 308, 1997
9. Dawson, N. A., Conaway, M., Halabi, S., Winer, E. P., Small, E. J., Lake, D. et al: A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma: cancer and leukemia group B study 9181. Cancer, 88: 825, 2000
10. Pendyala, L., Creaven, P. J., Huben, R., Tremblay, D. and Bertagna, C.: Pharmacokinetics of Anandron in patients with advanced carcinoma of the prostate. Cancer Chemother Pharmacol, 22: 69, 1988
11. Janknegt, R. A., Abbou, C. C., Bartoletti, R., Bernstein-Hahn, L., Bracken, B., Brisset, J. M. et al: Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial. J Urol, 149: 77, 1993
12. Desai, A., Stadler, W. M. and Vogelzang, N.: Nilutamide: possible utility as second-line hormonal agent. Urology, 58: 1016, 2001
13. Eastham, J. A. and Sartor, O.: Nilutamide response after flutamide failure in post-orchiectomy progressive prostate cancer. J Urol, 159: 990, 1998
14. Bubley, G. J., Carducci, M., Dahut, W., Dawson, N., Daliani, D., Eisenberger, M. et al: Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol, 17: 3461, 1999
15. Small, E. J. and Vogelzang, N. J.: Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm. J Clin Oncol, 15: 382, 1997
16. Small, E. J., McMillan, A., Meyer, M., Chen, L., Slichenmyer, W. J., Lenehan, P. F. et al: Serum prostate-specific antigen as a marker of clinical outcome in hormone-refractory prostate cancer patients: association with progression-free survival, pain end points, and survival. J Clin Oncol, 19: 1304, 2001